We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00475241
First Posted: May 21, 2007
Last Update Posted: November 10, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
VA Office of Research and Development
Results First Submitted: October 27, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Combat Disorders
Posttraumatic Stress Disorder
Interventions: Behavioral: Prolonged Exposure therapy for PTSD
Behavioral: Present centered therapy for PTSD

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Prolonged Exposure

Prolonged exposure therapy for PTSD

Prolonged Exposure therapy for PTSD: exposure-based treatment for PTSD

Present Centered Therapy

Present centered therapy for PTSD

Present centered therapy for PTSD: present focused coping and problem solving for PTSD


Participant Flow:   Overall Study
    Prolonged Exposure   Present Centered Therapy
STARTED   18   18 
COMPLETED   11   15 
NOT COMPLETED   7   3 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Prolonged Exposure

Prolonged exposure therapy for PTSD

Prolonged Exposure therapy for PTSD: exposure-based treatment for PTSD

Present Centered Therapy

Present centered therapy for PTSD

Present centered therapy for PTSD: present focused coping and problem solving for PTSD

Total Total of all reporting groups

Baseline Measures
   Prolonged Exposure   Present Centered Therapy   Total 
Overall Participants Analyzed 
[Units: Participants]
 11   15   26 
Age 
[Units: Years]
Mean (Standard Deviation)
 29.8  (6.5)   32.9  (7.2)   31.6  (7.0) 
Gender 
[Units: Participants]
     
Female   2   0   2 
Male   9   15   24 
Region of Enrollment 
[Units: Participants]
     
United States   11   15   26 
CAPS [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 79.2  (12.1)   77.4  (12.1)   78.2  (11.9) 
[1] Clinician Adminstered PTSD Scale (CAPS) assesses PTSD symptom severity. Scores range from 0 to 136. Higher scores represent more severe symptoms.


  Outcome Measures

1.  Primary:   Clinician Administered PTSD Scale (Pre & Posttreatment)   [ Time Frame: PostTreatment (Week 12) ]

2.  Secondary:   Psychophysiological Reactivity Will be Assessed Using a Biopac MP-100 Physiology Recording System for Measurement of Heart Rate (Electrocardiography, ECG), Skin Conductance, Respiration, and End-tidal pCO2 (Pre, Mid, Posttreatment, 3 and 6 mo FU).   [ Time Frame: pre, mid, post, 3 and 6 mo FU ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   HPA Axis Reactivity Will be Assessed With Collection of Salivary Cortisol at Each Major Assessment. Cortisol Response to Awakening, Our Measure of General Stress Reactivity, Will be Calculated.   [ Time Frame: pre, mid, post, 3 and 6 mo FU ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   All of Below Measures Are Taken at the Major Assessment Points.- Beck Depression Inventory-II- Depression Anxiety Stress Scale- Posttraumatic Cognitions Inventory- Client Satisfaction Questionnaire   [ Time Frame: pre, mid, post, 3 and 6 mo FU ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Sheila A.M. Rauch
Organization: VA Ann Arbor Healthcare System
phone: 734-845-3545
e-mail: sherauch@med.umich.edu


Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00475241     History of Changes
Other Study ID Numbers: CDA-2-010-06F
First Submitted: May 17, 2007
First Posted: May 21, 2007
Results First Submitted: October 27, 2014
Results First Posted: November 10, 2014
Last Update Posted: November 10, 2014